Vesalius Biocapital III
Vesalius Biocapital III is a €70 million fund that invests in medtech, e-health initiatives and drug development in Europe. It was launched in 2017 by Luxembourg-based Vesalius Biocapital, a life sciences venture capital firm founded in 2007. Preceding Vesalius Biocapital III were Vesalius Biocapital I, with €76 million under management and Vesalius Biocapital II, which has €78 million invested; both funds have 11 portfolio companies each.Its recent investments include in Portuguese home physiotherapy tech solution SWORD Health's 2021 $25m Series B and in the 2020 $9m second phase of its Series A round as well as in the 2020 €22m Series B round of German biotech Topas Therapeutics.
The rest of the content is only available if you are logged in.